Cited 30 times in
Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강승민 | - |
dc.contributor.author | 송선옥 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 정인경 | - |
dc.date.accessioned | 2015-01-06T16:30:33Z | - |
dc.date.available | 2015-01-06T16:30:33Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98238 | - |
dc.description.abstract | It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had ≥ 2 clinic visits between November 2005 and June 2011 at one of four tertiary referral hospitals in Korea. A prevalent case-control analysis nested within the cohort was conducted to further adjust confounders. A total of 101,953 control patients and 11,240 pioglitazone-treated patients were included, in which there were 237 and 30 cases of incidental bladder cancer (64.9 and 54.9 per 100,000 person-years; age, sex-adjusted HR 1.135, 95% confidence interval [CI] 0.769-1.677), respectively. In the prevalent case-control analysis nested within the cohort, use of pioglitazone for a duration of > 6 months, but not ever use of pioglitazone, was associated with an increased rate of bladder cancer as compared to never use of pioglitazone. In conclusion, we failed to exclude the possible association between use of pioglitazone for a duration of > 6 months and bladder cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 238~242 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Case-Control Studies | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/complications | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Tertiary Care Centers | - |
dc.subject.MESH | Thiazolidinediones/therapeutic use* | - |
dc.subject.MESH | Urinary Bladder Neoplasms/complications | - |
dc.subject.MESH | Urinary Bladder Neoplasms/diagnosis* | - |
dc.subject.MESH | Urinary Bladder Neoplasms/epidemiology | - |
dc.title | Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Sang-Man Jin | - |
dc.contributor.googleauthor | Sun Ok Song | - |
dc.contributor.googleauthor | Chang Hee Jung | - |
dc.contributor.googleauthor | Jin-Sun Chang | - |
dc.contributor.googleauthor | Sunghwan Suh | - |
dc.contributor.googleauthor | Seung Min Kang | - |
dc.contributor.googleauthor | Inkyung Jung | - |
dc.contributor.googleauthor | Cheol-Young Park | - |
dc.contributor.googleauthor | Jae Hyeon Kim | - |
dc.contributor.googleauthor | Jae Hyoung Cho | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.identifier.doi | 10.3346/jkms.2014.29.2.238 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00045 | - |
dc.contributor.localId | A02029 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A03693 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 24550651 | - |
dc.subject.keyword | Diabetes Mellitus, Type 2 | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | Pioglitazone | - |
dc.subject.keyword | Urinary Bladder Neoplasms | - |
dc.contributor.alternativeName | Kang, Seung Min | - |
dc.contributor.alternativeName | Song, Sun Ok | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.alternativeName | Jung, In Kyung | - |
dc.contributor.affiliatedAuthor | Kang, Seung Min | - |
dc.contributor.affiliatedAuthor | Song, Sun Ok | - |
dc.contributor.affiliatedAuthor | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | Jung, In Kyung | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 238 | - |
dc.citation.endPage | 242 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.29(2) : 238-242, 2014 | - |
dc.identifier.rimsid | 50739 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.